Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover. http://www.nature.com/nbt/podcast/index.html
Rights and permissions
About this article
Cite this article
First Rounders Podcast: Colin Goddard. Nat Biotechnol 33, 583 (2015). https://doi.org/10.1038/nbt.3255
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3255